Our results show IGF1R to be associated with cytarabine in vitro chemosensitivity and in conjunction with reports of specific targeting of IGF1/IGF1R signaling pathway having potent anti-leukemic activity in AML cells with constitutive PI3K activation, makes it a likely drug target. The gene discussed is IGF1R; the disease is acute myeloid leukemia.